Please provide your email address to receive an email when new articles are posted on . Patients receiving tofacitinib had fewer enthesitis relapses following initial resolution after 1 or 3 months.

Patients with psoriatic arthritis with enthesitis are more likely to have severe disease than patients without enthesitis, and they and their physicians are less likely to be satisfied with their ...

Please provide your email address to receive an email when new articles are posted on . In patients with psoriatic arthritis, secukinumab and adalimumab demonstrated similar results regarding ...

The severity of enthesitis in psoriatic arthritis is a potential marker for severe disease and joint damage, a cross-sectional study found. For instance, a 10-unit increase on the Madrid Sonographic ...

Enthesitis is estimated to affect between 30% and 70% of patients with AS and is often underdiagnosed in routine practice. Secukinumab has been shown to provide rapid and sustained enthesitis ...

Treatment with guselkumab led to improvements in disease activity over 1 year among patients with PsA and showed a high retention rate.

Psoriatic arthritis is a long-term condition that affects both the skin and joints. It commonly develops in people with ...

Credit: Getty Images. The 52-week double-blind, placebo-controlled ULTIMATE study included 166 adult biologic-naive patients with active psoriatic arthritis. Novartis announced results from a phase 3b ...

Around 5% of patients treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis experience musculoskeletal (MSK) symptoms, according to the results of a descriptive study. The main ...

The US Food and Drug Administration has approved the dual interleukin (IL)-12 and IL-23 inhibitor ustekinumab (Stelara) for the treatment of juvenile psoriatic arthritis (jPsA) in patients aged 6 ...